This Research Topic is the second volume of the 'Community Series in Neurobiological Biomarkers for Developing Novel Treatments of Substance and Non-Substance Addiction'. Please see the first volume here. Many people suffer from substance (from nicotine or alcohol to heroin, methamphetamine, cocaine, etc) or non-substance (from gaming/gambling to shopping, internet, smartphone, etc) addiction. Both types of addiction are associated with severe health, economic and social consequences and are far too often result in both familial and personal tragedies. Unfortunately, current treatments are not very effective for either substance or non-substance addiction so novel treatments are desperately needed. For example, for nicotine addiction, despite very well-documented health risks of cigarette smoking and its economic and societal costs, globally, more than 30% of males still smoke, and although many smokers desire to quit, only approximately 5-30% will achieve abstinence with 6 months or more of the best available current treatments. And the story for nicotine addiction is far from unique, presenting a huge challenge for the entire addiction field. Therefore, there is a vital need to improve outcomes for the treatment of both substance and non-substance addictions. Recent work exploring neurobiological mechanisms of the treatment response at the molecular, cellular and systems levels with a broad range of technologies, such as Magnetic Resonance Imaging (MRI), genetics and genomics, have opened new avenues for developing novel treatments through the detection of neurobiological biomarkers predicting efficacious outcomes in addicted patients.

This book focuses on the similarities and differences between substance and non-substance addictions. It discusses in detail the mechanisms, diagnosis and treatment of substance and non-substance addictions, and addresses selected prospects that will shape future studies on addiction. Addiction is a global problem that costs millions of lives tremendous damage year after year. There are mainly two types of addition: substance addiction (e.g., nicotine, alcohol, cannabis, heroin, stimulants, etc.) and non-substance addiction (e.g., gambling, computer gaming, Internet, etc.). Based on existing evidence, both types of addiction produce negative impacts on individuals’ physical, mental, social and financial well-being, and share certain common mechanisms, which involve a dysfunction of the neural reward system and specific gene transcription factors. However, there are also key differences between these two types of addiction. Covering these aspects systematically, the book will provide researchers and graduate students alike a better understanding of drug and behavioral addictions.

Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system. Given the promising potential and necessity for neuroscience biomarkers, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened a public workshop and released the workshop summary entitled Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships. The workshop brought together experts from multiple areas to discuss the most promising and practical arenas in neuroscience in which biomarkers will have the greatest impact. The main objective of the workshop was to identify and discuss biomarker targets that are not currently being aggressively pursued but that could have the greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.

Brain imaging technology remains at the forefront of advances in both our understanding of the brain and our ability to diagnose and treat brain disease and disorders. Imaging of the Human Brain in Health and Disease examines the localization of neurotransmitter receptors in the nervous system of normal, healthy humans and compares that with humans who are suffering from various neurologic diseases. Opening chapters introduce the basic science of imaging neurotransmitters, including sigma, acetylcholine, opioid, and dopamine receptors. Imaging the healthy and diseased brain includes brain imaging of anger, pain, autism, the release of dopamine, the impact of cannabinoids, and Alzheimer's disease. This book is a valuable companion to a wide range of scholars, students, and researchers in neuroscience, clinical neurology, and psychiatry, and provides a detailed introduction to the application of advanced imaging to the treatment of brain disorders and disease. - A focused introduction to imaging healthy and diseased brains - Focuses on the primary neurotransmitter release - Includes sigma, acetylcholine, opioid, and dopamine receptors - Presents the imaging of healthy and diseased brains via anger, pain, autism, and Alzheimer's disease

In a book sure to inspire controversy, Gene Heyman argues that conventional wisdom about addiction—that it is a disease, a compulsion beyond conscious control—is wrong. Drawing on psychiatric epidemiology, addicts’ autobiographies, treatment studies, and advances in behavioral economics, Heyman makes a powerful case that addiction is voluntary. He shows that drug use, like all choices, is influenced by preferences and goals. But just as there are successful dieters, there are successful ex-addicts. In fact, addiction is the psychiatric disorder with the highest rate of recovery. But what ends an addiction? At the heart of Heyman’s analysis is a startling view of choice and motivation that applies to all choices, not just the choice to use drugs. The conditions that promote quitting a drug addiction include new information, cultural values, and, of course, the costs and benefits of further drug use. Most of us avoid becoming drug dependent, not because we are especially rational, but because we loathe the idea of being an addict. Heyman’s analysis of well-established but frequently ignored research leads to unexpected insights into how we make choices—from obesity to McMansionization—all rooted in our deep-seated tendency to consume too much of whatever we like best. As wealth increases and technology advances, the dilemma posed by addictive drugs spreads to new products. However, this remarkable and radical book points to a solution. If drug addicts typically beat addiction, then non-addicts can learn to control their natural tendency to take too much.

With recent studies using genetic, epigenetic, and other molecular and neurochemical approaches, a new era has begun in understanding pathophysiology of suicide. Emerging evidence suggests that neurobiological factors are not only critical in providing potential risk factors but also provide a promising approach to develop more effective treatment and prevention strategies. The Neurobiological Basis of Suicide discusses the most recent findings in suicide neurobiology. Psychological, psychosocial, and cultural factors are important in determining the risk factors for suicide; however, they offer weak prediction and can be of little clinical use. Interestingly, cognitive characteristics are different among depressed suicidal and depressed nonsuicidal subjects, and could be involved in the development of suicidal behavior. The characterization of the neurobiological basis of suicide is in delineating the risk factors associated with suicide. The Neurobiological Basis of Suicide focuses on how and why these neurobiological factors are crucial in the pathogenic mechanisms of suicidal behavior and how these findings can be transformed into potential therapeutic applications.

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

Based on the study of neuroscientific developments and innovations, examined from different angles, this Handbook provides a comprehensive overview of the international neuroethical debate, and offers unprecedented insights into the impact of neuroscientific research, diagnosis, and therapy. Neuroethics – as a multi-disciplinary and inter-disciplinary endeavor – examines the implications of the neurosciences for human beings in general and for their self-understanding and their social interactions in particular. The range of approaches adopted in neuroethics and thus in this handbook includes but is not limited to historical, anthropological, ethical, philosophical, theological, sociological and legal approaches. The Handbook deals with a plethora of topics, divided into in three parts: the first part contains discussions of theories of neuroethics and how neuroscience impacts on our understanding of personal identity, free will, and other philosophical concepts. The second part is dedicated to issues involved in current and future clinical applications of neurosciences, such as brain stimulation, brain imaging, prosthetics, addiction, and psychiatric ethics. The final part deals with neuroethics and society and includes chapters on neurolaw, neurotheology, neuromarketing, and enhancement.

The Neurobiology of Bipolar Disorder: Road to Novel Therapeutics combines the basic neurobiology of bipolar disorder with discussions of the most recent advances in research, including the interacting pathways implicated in the pathophysiology of bipolar disorder, genetic approaches and the pharmacogenomics of bipolar disorder. The basic foundational understanding of the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research combine to aid advanced students and researchers in their understanding of bipolar disorder management using novel and fast-acting pharmaceutical and neuromodulatory approaches. - Aids readers in understanding bipolar disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations - Covers a range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments to novel therapeutics - Synthesizes a discussion of the cellular and molecular mechanisms underlying symptoms with clinical aspects of bipolar disorder